Acessibilidade / Reportar erro

Right Atrium Tumor Extension Through the Inferior Vena Cava. Considerations About Nine Cases Operated Under Cardiopulmonary Bypass

Abstract

Introduction:

Adrenocortical and renal cell carcinomas rarely invade the right atrium (RA). These neoplasms need surgical treatment, are very aggressive and have poor prognostic and surgical outcomes.

Case series:

We present a retrospective cohort of nine cases of RA invasion through the inferior vena cava (four adrenocortical carcinomas and five renal cell carcinomas). Over 13 years (2002-2014), nine patients were operated in collaboration with the team of urologists. Surgery was possible in all patients with different degrees of technical difficulty. All patients were operated considering the imaging examinations with the aid of CPB. In all reported cases (renal or suprarenal), the decision to use CPB with deep hypothermic circulatory arrest (DHCA) on surgical strategy was decided by the team of urological and cardiac surgeons.

Conclusion:

Data retrospectively collected from patients of public hospitals reaffirm: 1) Low incidence with small published series; 2) The selected cases did not represent the whole historical casuistry of the hospital, since they were selected after the adoption of electronic documentation; 3) Demographic data and references reported in the literature were presented as tables to avoid wordiness; 4) The series highlights the propensity to invade the venous system; 5) Possible surgical treatment with the aid of CPB in collaboration with the urology team; 6) CPB with DHCA is a safe and reliable option; 7) Poor prognosis with disappointing late results, even considering the adverse effects of CPB on cancer prognosis are expected but not confirmed.

Keywords:
Adrenocortical Carcinoma; Carcinoma, Renal Cell; Vena Cava, Inferior; Circulatory Arrest, Deep Hypothermia; Kidney; Urological Surgical Procedures; Treatment Outcome

Abbreviations, acronyms & symbols ACC = Adrenocortical carcinoma CPB = Cardiopulmonary bypass CT = Computed tomography DHCA = Deep hypothermic circulatory arrest IVC = Inferior vena cava MRI = Magnetic resonance imaging PET = Positron emission tomography PTFE = Polytetrafluoroethylene RA = Right atrium RCC = Renal cell carcinoma

INTRODUCTION

Adrenocortical carcinoma (ACC) and renal cell carcinoma (RCC) are aware malignancies that occasionally present extending into the right atrium (RA) through the inferior vena cava. Patients can present with a variety of signs and symptoms, depending on the extent of the tumor. These neoplasms demand surgical treatment, are very aggressive and have poor prognosis and surgical outcomes. Therefore, this unusual pathological situation has to be in mind of the “heart team”. The discovery of a mass in the right atrium obliges the clinician to perform a broad differential diagnosis between a primary cardiac tumor (myxoma being the most frequent), invasion of an extracardiac tumor, vegetations on the tricuspid valve and atrial thrombus. Tumor extension with vena cava thrombosis is a relatively frequent complication of renal carcinoma, but only exceptionally reaches the right atrium. It is also exceptional that this was a chance finding in an asymptomatic patient[11 Nogales Asensio JM, Reyes González Fernández M, Alonso Bravo M, Merchán Herrera A. Kidney tumour mimicking cardiac mass. Int J Cardiol. 2006;106(3):401-3. doi:10.1016/j.ijcard.2004.12.086.
https://doi.org/10.1016/j.ijcard.2004.12...
].

As an overview, Castro-Dominguez et al.[22 Castro-Dominguez Y, Samad F, Hashim H, Waller A. Extension of adrenocortical carcinoma into the right atrium. Pak J Med Sci. 2017;33(2):510-2. doi:10.12669/pjms.332.12877.
https://doi.org/10.12669/pjms.332.12877...
] stated that ACC is a highly aggressive malignant neoplasm with an incidence rate of 1 to 2 cases per million people per year. Overall 5-year survival is poor, ranging from 15 to 44% in reported series. Multimodality imaging with echocardiogram, computed tomography (CT), positron emission tomography (PET) and magnetic resonance imaging (MRI) aids not only in establishing the diagnosis but also in anatomic evaluation to determine the best surgical approach[22 Castro-Dominguez Y, Samad F, Hashim H, Waller A. Extension of adrenocortical carcinoma into the right atrium. Pak J Med Sci. 2017;33(2):510-2. doi:10.12669/pjms.332.12877.
https://doi.org/10.12669/pjms.332.12877...
].

According to Locali et al., based on a series of 14 cases, these tumors are routine in urological surgery. But they are important in the context of cardiovascular surgery due to possible complications with intracaval and/or intracardiac thrombi. Studies in this area, however, are mostly case reports or case series with small sample numbers. Due mainly to the rarity of this complication, few studies have been performed with larger case numbers, providing reliable conclusions[33 Locali RF, Matsuoka PK, Cherbo T, Gabriel EA, Buffolo E. Renal and adrenal tumors with cardiac invasion: immediate surgical results in 14 patients. Arq Bras Cardiol. 2009 Mar;92(3):168-76. doi:10.1590/s0066-782x2009000300003.
https://doi.org/10.1590/s0066-782x200900...
].

Therefore, the objective of this presentation was based on the relative scarcity of reported cases, presenting nine cases of RA invasion through the inferior vena cava (four adrenocortical and five renal tumors) performed over 13 years.

Cases Series

Over 13 years (2002-2014), nine patients were operated in collaboration with the team of urologists. The patients were allocated into 2 groups presented in Table 1.

Table 1
Demographic data.

Suprarenal group (n=4): Gender (3 males, 1 female); Age (03, 05, 52, 62 years old, respectively); CPB time (165, 75, 85, 195 min, respectively); mortality rate (two patients died in the immediate postoperative day; two survived 6 and 15 months, respectively). Renal group (n=5): Gender (3 males, 2 females); Age (55, 57, 60, 61, 89 years old, respectively); CPB time (175, 165, 140, 60, 215 min, respectively); mortality rate (two patients died in the immediate postoperative day; two survived 12 months, and one survived 143 months, respectively). The renal group did not consider the renal pelvis. Figure 1 shows an intraoperative renal carcinoma with invasion of the inferior vena cava. The CPB data are presented in Table 1. All cases submitted are classified as Level 4 according to the Mayo Clinic classification (Figure 2)[44 Calero A, Armstrong PA. Renal cell carcinoma accompanied by venous invasion and inferior vena cava thrombus: classification and operative strategies for the vascular surgeon. Semin Vasc Surg. 2013;26(4):219-25. doi:10.1053/j.semvascsurg.2014.06.015.
https://doi.org/10.1053/j.semvascsurg.20...
].

Fig. 1
Intraoperative pictures (patient on CPB). A=Right atrium opening; B=Tumor protruding into the right atrium; C=Intracardiac tumor excision; D=Macroscopic aspect of the excised tumor

Fig. 2
Classification of tumor thrombus level according to the Mayo staging system. (Adapted from Calero A, Armstrong PA. Semin Vasc Surg. 2013 Dec;26:219-25).

Patients were operated on mainly considering imaging CT scans that were good enough for tumor observations (Figure 3).

Fig. 3
CT image. A=suprarenal tumor (*); B=renal tumor (arrow).

In all reported cases (renal or suprarenal), the use of CPB with deep hypothermic circulatory arrest (DHCA) and the surgical strategy were decided by the team of urological and cardiac surgeons. In summary, through a modified chevron incision, starting two fingerbreadths below the right costal margin and extending laterally to the midaxillary line, the kidney was exposed and mobilized laterally and posteriorly, the perirenal collateral circulation and the renal artery were ligated. Infrarenal inferior vena cava (IVC) and the contralateral renal vein were dissected. Liver mobilization, when necessary, was performed. After the abdominal step, a median sternotomy was performed, the pericardium was opened, CPB was installed and DHCA was carried out (Figure 1).

Only once the aorta was clamped for infusion of cardioplegia in a patient who had a mild coronary lesion. In other cases, induced ventricular fibrillation was expected, always maintaining good drainage of the left chambers. After CPB, the IVC was incised from the liver border to the renal vein and the tumor was removed in block. After tumor removal, saline was injected to wash the proximal region of the IVC, low flow CPB was carried out, and body rewarming according to the total circulatory arrest protocol. When necessary, polytetrafluoroethylene (PTFE) or bovine pericardium patches were used for the IVC reconstruction. Histological samples are presented in Figure 4, confirming the diagnosis.

Fig. 4
Histology: A=Sample of adrenocortical carcinoma attached to the venous wall (H&E, 200X); B=Clear cell renal cell carcinoma with scant stroma and delicate vasculature (H&E, 400X).

DISCUSSION

As already mentioned, adrenocortical carcinomas and renal cell carcinomas (RCC) are rare malignancies. According to Spanish data, collected between early 1975 and April 1997, among 212 patients who underwent surgery for RCC, only 2 cases showed right atrial extension[55 González Martín M, Chantada Abal V, Alvarez Castelo LM, Duarte Novo J, Serrano Barrientos J, Sánchez Rodríguez J. [Renal carcinoma with tumor thrombus in the vena cava and auricle. Experience and review]. Arch Esp Urol. 1998;51(1):44-53. Spanish.]. Among the metastatic tumors of the heart, those arising from the genitourinary system are amongst the most common[66 Butany J, Leong SW, Carmichael K, Komeda M. A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol. 2005;21(8):675-80.]. Most of the case reports references were presented in Table 2.

Table 2
Selected references.

Patients can present with a variety of signs and symptoms, depending on the extent of the tumor. CT scan of chest and abdomen represents the gold standard in ACC staging, while magnetic resonance imaging (MRI) is preferred for tumor thrombus characterization. Complete surgical resection is the only curative option for localized disease. Kidney-sparing surgery should be performed when possible. Hedican and Marshall[77 Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158(6):2056-61. doi:10.1016/s0022-5347(01)68152-7.
https://doi.org/10.1016/s0022-5347(01)68...
] reported three patients with adrenocortical carcinoma with tumor thrombus and reviewed 26 patients described in the literature from 1972 to 1997 regarding presentation, management and outcome. Among 15 patients, Nakahoma et al.[88 Nakanoma T, Ueno M, Nonaka S, Tsukamoto T, Deguchi N. [Left adrenocortical cancer with inferior vena cava tumor thrombus--a case report]. Nihon Hinyokika Gakkai Zasshi. 2001;92(1):34-7. doi:10.5980/jpnjurol1989.92.34. Japanese.
https://doi.org/10.5980/jpnjurol1989.92....
] presented a case that seems to be the 8th case report of left adrenocortical cancer with tumor thrombus extension into IVC and right atrium. More recently, Castro-Dominguez et al.[22 Castro-Dominguez Y, Samad F, Hashim H, Waller A. Extension of adrenocortical carcinoma into the right atrium. Pak J Med Sci. 2017;33(2):510-2. doi:10.12669/pjms.332.12877.
https://doi.org/10.12669/pjms.332.12877...
] reported one case of a large ACC with extension to the IVC and right atrium (RA). Our nine cases will be added to the medical literature without changing the low incidence paradigm with small published series, because they do not represent the whole historical casuistry of the hospital, since they are chosen after the adoption of electronic documentation.

DHCA is the most commonly used method and allows complete tumor resection without increasing operative risk. The cardiothoracic team, considering the unusual situation, opted for routine cardiac surgeries (median sternotomy, careful venae cavaes dissections). Deep hypothermia was employed, and due to technical difficulty in one patient, the heart was arrested with cold blood potassium cardioplegia. However, further studies are needed to evaluate the possible role of alternative methods compared to deep hypothermic circulatory arrest[99 Gaudino M, Lau C, Cammertoni F, Vargiu V, Gambardella I, Massetti M, et al. Surgical treatment of renal cell carcinoma with cavoatrial involvement: a systematic review of the literature. Ann Thorac Surg. 2016;101(3):1213-21. doi:10.1016/j.athoracsur.2015.10.003.
https://doi.org/10.1016/j.athoracsur.201...
,1010 Dashkevich A, Bagaev E, Hagl C, Pichlmaier M, Luehr M, von Dossow V, et al. Long-term outcomes after resection of stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest. Eur J Cardiothorac Surg. 2016;50(5):892-7. doi:10.1093/ejcts/ezw136.
https://doi.org/10.1093/ejcts/ezw136...
].

The outcome evaluation confirmed the well-established poor prognosis with disappointing results (two patients survived for more than 12 years, four died in the early postoperative period and, among the others, four patients did not live longer than 12 months). One patient died during surgery due to intractable blood clotting disorder; two developed vasospastic syndrome and died on the second postoperative day; a third patient died during the performance of the arteriovenous fistula to treat severe acute sufficiency. The other five patients presented dissemination of the disease and died due to respiratory failure.

About the possible influence of the type of neoplasia, we did not find any publications directly correlating the type of neoplasia with possible dissemination caused or favored by CPB. In other words, it cannot be said that a particular kind of cancer is more susceptible to propagation by CPB. The application of CPB in oncologic patients is still controversial, with the possible disadvantages of hematogenous dissemination of tumor cells. There are two possible mechanisms through which CPB might contribute to the hematogenous dissemination of tumor cells. First, tumor cells contaminated in the blood reservoir might spread through the arterial cannula. Second, the CPB homeostasis imbalance may contribute to the dissemination of neoplastic cells preoperatively suppressed by the host defense system. Finally, further research is needed to know whether the transient immunosuppression associated with CPB can promote the spread and growth of pre-existing cancer cells. However, adverse effects of CPB on cancer prognosis are expected but have not been confirmed[1111 Braile DM, Évora PRB. Cardiopulmonary bypass and cancer dissemination: a logical but unlikely association. Braz J Cardiovasc Surg. 2018;33(1):I-II. doi:10.21470/1678-9741-2018-0600.
https://doi.org/10.21470/1678-9741-2018-...
,1212 Évora PRB, Albuquerque AAS, Nadai TR, Mente ED, Sankarankuty AK, Castro-E-Silva O. The cardiopulmonary bypass and cancer dissemination puzzle. Acta Cir Bras. 2018;33(11):1037-42. doi:10.1590/s0102-865020180110000010.
https://doi.org/10.1590/s0102-8650201801...
].

CONCLUSION

The present data retrospectively collected from public hospital patients reaffirm: 1) Low incidence with small published series; 2) The selected cases did not represent the whole historical casuistry of the hospital, since they are selected after the adoption of electronic documentation; 3) Demographic data and references reported in the literature were presented as tables to avoid wordiness; 4) The series highlights the propensity to invade the venous system; 5) Possible surgical treatment with the aid of CPB in collaboration with the urology team; 6) CPB with DHCA is a safe and reliable option; 7) Poor prognosis with disappointing late results, even considering that adverse effects of CPB on cancer prognosis are expected but have not been confirmed.

Author's roles & responsibilities FC Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published STJ Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published SB Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published RBR Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published AJR Substantial contributions to the conception or design of the work; final approval of the version to be published WVAV Substantial contributions to the conception or design of the work; final approval of the version to be published PRBE Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual contente; final approval of the version to be published
  • This study was carried out at Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil.
  • Financial support: FAEPA, FAPESP, CNPq

REFERENCES

  • 1
    Nogales Asensio JM, Reyes González Fernández M, Alonso Bravo M, Merchán Herrera A. Kidney tumour mimicking cardiac mass. Int J Cardiol. 2006;106(3):401-3. doi:10.1016/j.ijcard.2004.12.086.
    » https://doi.org/10.1016/j.ijcard.2004.12.086
  • 2
    Castro-Dominguez Y, Samad F, Hashim H, Waller A. Extension of adrenocortical carcinoma into the right atrium. Pak J Med Sci. 2017;33(2):510-2. doi:10.12669/pjms.332.12877.
    » https://doi.org/10.12669/pjms.332.12877
  • 3
    Locali RF, Matsuoka PK, Cherbo T, Gabriel EA, Buffolo E. Renal and adrenal tumors with cardiac invasion: immediate surgical results in 14 patients. Arq Bras Cardiol. 2009 Mar;92(3):168-76. doi:10.1590/s0066-782x2009000300003.
    » https://doi.org/10.1590/s0066-782x2009000300003
  • 4
    Calero A, Armstrong PA. Renal cell carcinoma accompanied by venous invasion and inferior vena cava thrombus: classification and operative strategies for the vascular surgeon. Semin Vasc Surg. 2013;26(4):219-25. doi:10.1053/j.semvascsurg.2014.06.015.
    » https://doi.org/10.1053/j.semvascsurg.2014.06.015
  • 5
    González Martín M, Chantada Abal V, Alvarez Castelo LM, Duarte Novo J, Serrano Barrientos J, Sánchez Rodríguez J. [Renal carcinoma with tumor thrombus in the vena cava and auricle. Experience and review]. Arch Esp Urol. 1998;51(1):44-53. Spanish.
  • 6
    Butany J, Leong SW, Carmichael K, Komeda M. A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol. 2005;21(8):675-80.
  • 7
    Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158(6):2056-61. doi:10.1016/s0022-5347(01)68152-7.
    » https://doi.org/10.1016/s0022-5347(01)68152-7
  • 8
    Nakanoma T, Ueno M, Nonaka S, Tsukamoto T, Deguchi N. [Left adrenocortical cancer with inferior vena cava tumor thrombus--a case report]. Nihon Hinyokika Gakkai Zasshi. 2001;92(1):34-7. doi:10.5980/jpnjurol1989.92.34. Japanese.
    » https://doi.org/10.5980/jpnjurol1989.92.34
  • 9
    Gaudino M, Lau C, Cammertoni F, Vargiu V, Gambardella I, Massetti M, et al. Surgical treatment of renal cell carcinoma with cavoatrial involvement: a systematic review of the literature. Ann Thorac Surg. 2016;101(3):1213-21. doi:10.1016/j.athoracsur.2015.10.003.
    » https://doi.org/10.1016/j.athoracsur.2015.10.003
  • 10
    Dashkevich A, Bagaev E, Hagl C, Pichlmaier M, Luehr M, von Dossow V, et al. Long-term outcomes after resection of stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest. Eur J Cardiothorac Surg. 2016;50(5):892-7. doi:10.1093/ejcts/ezw136.
    » https://doi.org/10.1093/ejcts/ezw136
  • 11
    Braile DM, Évora PRB. Cardiopulmonary bypass and cancer dissemination: a logical but unlikely association. Braz J Cardiovasc Surg. 2018;33(1):I-II. doi:10.21470/1678-9741-2018-0600.
    » https://doi.org/10.21470/1678-9741-2018-0600
  • 12
    Évora PRB, Albuquerque AAS, Nadai TR, Mente ED, Sankarankuty AK, Castro-E-Silva O. The cardiopulmonary bypass and cancer dissemination puzzle. Acta Cir Bras. 2018;33(11):1037-42. doi:10.1590/s0102-865020180110000010.
    » https://doi.org/10.1590/s0102-865020180110000010

Publication Dates

  • Publication in this collection
    23 Sept 2019
  • Date of issue
    Nov-Dec 2019

History

  • Received
    10 Feb 2019
  • Accepted
    13 May 2019
Sociedade Brasileira de Cirurgia Cardiovascular Rua Afonso Celso, 1178 Vila Mariana, CEP: 04119-061 - São Paulo/SP Brazil, Tel +55 (11) 3849-0341, Tel +55 (11) 5096-0079 - São Paulo - SP - Brazil
E-mail: bjcvs@sbccv.org.br